Pfizer Will Retain Infliximab Biosimilar In US After Hospira Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
While European Union requires Pfizer to divest its infliximab candidate in Europe as condition of acquisition, FTC demands only that it sell off four generics.